All News 22 December, 2025First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25 18 December, 2025Xinnate Completes Oversubscribed Share Issue of SEK 38,5m 10 December, 2025Xinnate Receives FDA IND Approval for TCP-25, Enabling Pivotal Phase 2/3 STEP Study in Epidermolysis Bullosa 1 July, 2025Xinnate raises SEK 31 million in oversubscribed share issue 27 June, 2025New Addition to Xinnate’s Board: Dr Per Norlén, MD PhD 23 May, 2025Xinnate announces successful FDA meeting for TCP-25 14 January, 2025Xinnate receives Orphan Drug Designation from US FDA for TCP-25 17 December, 2024Xinnate AB partners with Destum Partners, Inc. a leading global, advisory firm 27 September, 2024Phase I Study Results of a Novel Immunomodulatory Peptide, TCP-25, for Treatment of Dystrophic Epidermolysis Bullosa 5 September, 2024Xinnate presents TCP-25 data at international dermatology congress 7 May, 2024Xinnate reports positive results from Phase 1 study with TCP-25, in patients with Epidermolysis Bullosa 18 March, 2024Xinnate completes Phase 1a/b study with TCP-25 7 February, 2024Xinnate secures 100 million SEK in financing and applies for a patent for the treatment of Epidermolysis Bullosa 18 March, 2023Xinnate appoints Anna-Karin Lindqvist as new COO19 October, 2022Approved clinical trial application for BioC gel on complex wounds15 September, 2022Excellent results from phase I study shows that the BioC gel is safe and well tolerated.15 July, 2022Funding secured for the next step of BioC clinical plan1 July, 2022Xinnate is awarded a prestigious grant from the US Department of Defense25 March, 2022Approved clinical trial application for First in Human study on BioC gel20 August, 2021New publication: BioC-coated dressing shows promising effect on both infection and inflammation26 October, 2020Funding secured for the first clinical study of BioC wound gel11 October, 2020Xinnate has received a prestigious Swedish Research Council grant18 January, 2020Xinnate is looking for a Chief Operating Officer16 January, 2020Great interest for the STM article and coverage in Nature Reviews Drug Discovery8 January, 2020Breakthrough results published in Science Translational Medicine
